Latest Takeda Pharma (TKPYY) Headlines Have Anti-
Post# of 4
Posted On: 03/11/2014 7:26:30 PM
Latest Takeda Pharma (TKPYY) Headlines
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
The Zacks Analyst Blog Highlights:Actavis, Sanofi, Takeda Pharmaceutical, Forest Laboratories and Iconix Brand Group
PR Newswire - Tue Mar 04, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Actavis, Inc. (NYSE:ACT-Free Report), Sanofi (NYSE:SNY-Free Report), Takeda Pharmaceutical Company Limited (OTC:TKPYY-Free Report), Forest Laboratories Inc. (NYSE:FRX-Free Report) and Iconix Brand Group Inc. (Nasdaq:ICON-Free Report).
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Actavis Challenges Patents - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 3:45PM CST
Actavis announced that it is seeking FDA approval for its generic versions of Multaq and Colcrys.
Sucampo Gains On Better-Than-Expected Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:20PM CST
Shares of Sucampo Pharmaceuticals gained 11.9% following the release of fourth quarter results on Feb 26, 2014.
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
Takeda Joins The Global CEO Initiative on Alzheimer's Disease
PR Newswire - Thu Feb 20, 9:30AM CST
The Global CEO Initiative (CEOi) on Alzheimer's Disease today announced that Takeda Pharmaceutical Company Limited ("Takeda") will join the CEOi as part of its effort to spur innovations in research and accelerate a means of prevention for Alzheimer's and Dementia, building momentum behind the G8's commitment to stop the disease by 2025.
Alnylam Widens Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 11:00AM CST
Alnylam's fourth quarter 2013 loss of 51 cents per share was wider than the Zacks Consensus Estimate of a loss of 48 cents.
Wider-than-Expected Q4 Loss at AMAG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 9:40AM CST
AMAG's fourth quarter 2013 loss of 17 cents per share was wider than the Zacks Consensus Estimate of a loss of 10 cents.
Seattle Genetics Achieves Sales Milestone Under ADCETRIS(R) (Brentuximab Vedotin) Collaboration with Takeda
Business Wire - Wed Feb 05, 8:00AM CST
Seattle Genetics, Inc. (Nasdaq: SGEN), today announced that it will receive a $5 million milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda). The milestone was triggered by Takeda surpassing annual ADCETRIS net sales of $100 million in its territories. The milestone will be recognized as royalty revenue in the first quarter of 2014.
Concise Analysis of the International Biomarkers - Discovery Techniques and Applications
M2 - Fri Jan 31, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/5nwd88/biomarkers) has announced the addition of the "Concise Analysis of the International Biomarkers - Discovery Techniques and Applications" report to their offering. Biomarker discovery techniques analyzed in this report include Bioimaging, Bioinformatics and Omics Technologies. On a broader geographic level, these technologies further drilled down to Bioimaging - Computed Tomography (CT), Magnetic Resonence Imaging (MRI), Ultrasound and Other; and Omics Technologies - Genomics, Metabolomics, Proteomics and Other. The study also explores the global market for therapeutic areas of biomarkers comprising Cardiology, Neurology, Oncology and Other. The report reviews, analyses and projects the Biomarkers market for global and the regional markets including the United States, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 10 independent countries across Europe - France, Germany, Italy, Spain, Sweden, the United Kingdom; and Asia-Pacific - Australia, China, India and Japan. Accounting for a lion's share of an estimated 47% in 2013, equating to US$18.9 billion, the United States leads the global market for Biomarkers. Growing at a robust compounded annual growth rate of 18.8% during the period 2013-2020, the global market is projected to touch US$63.2 billion. This 350 pages, global market report includes 100 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the market value in US$ by geographic region, biomarker discovery techniques and therapeutic area. Key Topics Covered: Part A: Global Market Perspective 1. Introduction 2. Key Market Trends 3. Key Major Players 4. Key Business Trends 5. Global Market Overview Part B: Regional Market Perspective Regional Market Overview 1. The United States 2. Europe 3. Asia-Pacific 4. Rest Of World Part C: Guide To The Industry 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part D: Annexure 1. Research Methodology 2. Feedback Companies Mentioned: - Abbott Laboratories - Bruker - Celera - Dr. Reddy's Laboratories - EMD Millipore - F. Hoffmann-La Roche - GE Healthcare - Johnson & Johnson - Nordion - Philips Healthcare - Ranbaxy Laboratories - Roche Diagnostics Corporation - Rosetta Genomics - Sanofi - Shimadzu Scientific Instruments - Siemens Healthcare - Siemens Healthcare Diagnostics - Sigma-Aldrich Corporation - Takeda Pharmaceutical Company - Thermo Fisher Scientific - UCB For more information visit http://www.researchandmarkets.com/research/5nwd88/biomarkers
Concise Analysis of the International Biopharmaceuticals Market
M2 - Fri Jan 31, 6:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/rcw555/biopharmaceuticals) has announced the addition of the "Biopharmaceuticals - A Global Market Overview" report to their offering. The pharmaceutical R&D pipeline and industry have been witnessing greater degree of dependence on biopharmaceuticals. Development of these products is being undertaken by a growing number of players in the pharmaceutical industry, which include the big pharma companies as also generic drug manufacturers, who are also engaged in developing biosimilars. In conjunction with the traditional small biopharmaceutical companies, the new bigger entrants have been focused on continually expanding the global biologics pipeline, implying that the number and proportion of new pharmaceuticals being commercialized would increasingly comprise biopharmaceuticals and not small molecule drugs. As the cost of developing biopharmaceuticals and bringing them to market is generally much higher, offering enhanced profit margins, it comes as no surprise that the global pharmaceutical industry would continue to rely on biopharmaceuticals for profits and innovation, in addition to its very survival. Even though the worldwide economic recession has been slow in recovering, the global pharmaceutical and biopharmaceutical industries have marched ahead, showing profitability and growth. According to estimates, more than 10k therapeutics are currently in the research and development stage, which include chemical substance pharmaceuticals or drugs and biotechnology-derived pharmaceuticals or biopharmaceuticals undergoing over 40k clinical trials. Key Topics Covered: Part A: Global Market Perspective 1. Introduction 2. Key Facts And Figures Of Biopharma Industry And Latest Approvals 3. Key Market Trends 4. Key Global Players 5. Key Business Trends 6. Global Market Overview Part B: Regional Market Perspective Regional Market Overview 1. North America 2. Europe 3. Asia-Pacific 4. South America 5. Rest Of World Part C: Guide To The Industry 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part D: Annexure 1. Research Methodology 2. The Questionnaire 3. Feedback Companies Mentioned: - Abbott Laboratories - Amgen - Astrazeneca - BASF - Bayer - Biocon - Biogen - Boehringer Ingelheim - Bristol-Myers Squibb Company - Daiichi Sankyo Company - Eli Lilly and Company - Genentech - Glaxosmithkline - Hospira - Johnson & Johnson - LG Life Sciences - Novartis - Novo Nordisk - Pfizer - Ranbaxy Laboratories - Roche Holding - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - UCB For more information visit http://www.researchandmarkets.com/research/rc...aceuticals
Skin Infections - Pipeline Review, H2 2013 Research Report
M2 - Fri Jan 31, 2:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/dq4mw3/skin_infections) has announced the addition of the "Skin Infections - Pipeline Review, H2 2013" report to their offering. 'Skin Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Infections. Skin Infections - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources Scope - A snapshot of the global therapeutic scenario for Skin Infections. - A review of the Skin Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Skin Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Takeda Pharmaceutical Company Limited Amorepacific Corporation Toyama Chemical Co., Ltd. Foamix Ltd. Anacor Pharmaceuticals, Inc. Lytix Biopharma AS MGB Biopharma Limited Pergamum AB Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/dq...infections About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
10-Q: STARRETT L S CO
Edgar Online - Thu Jan 30, 1:40PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 12-15
Concise Analysis of the International Peptide Therapeutics Market - Forecasts to 2018
M2 - Thu Jan 30, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/v65dnx/peptide) has announced the addition of the "Concise Analysis of the International Peptide Therapeutics Market - Forecasts to 2018" report to their offering. To exploit the emerging international peptide therapeutics market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for peptide molecules since chemotherapy, which is the major mode of treatment for cancer, is facing major challenges due to its inability to deliver the correct amount of drug directly. In addition, it affects the normal cells in the body. Peptide application in various other treatments has opened a promising avenue for future growth of this market. New routes of peptide administration are being investigated; however the parenteral route continues to dominate this market and accounted for a share of almost 86% of the entire market. Similarly, the technology market is ruled by LPPS (long phase peptide syntheses) and is anticipated to decline owing to huge demand for solid phase peptide syntheses and hybrid syntheses. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Global Peptide Therapeutics Market Dynamics 4 Global Peptide Therapeutics Market Analysis, By Applications 5 Global Peptide Therapeutics Market, by Route of Administration 6 Peptide Therapeutics Market - Generic & Innovative Segments 7 API Peptide Therapeutics Market, In-house Vs CMO 8 Peptide Therapeutics Market, By Technology 9 Peptide Therapeutics Market, By Geography 10 Market Share Analysis 11 Recommendations 12 Company Profiles Companies Mentioned: - Amgen - Amylin Pharmaceuticals - Bristol-Myers Squibb - AstraZeneca - Bachem Holding - Eli Lilly and Company - GlaxoSmithKline - Ipsen - Lonza - Merck & Co. - Novartis - Novo-Nordisk - Peptisyntha - Pfizer - PolyPeptide - Roche - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/v65dnx/peptide
Progenics Pharmaceuticals Inc names Dr Karen Ferrante to board
M2 - Thu Jan 30, 3:01AM CST
Oncology company Progenics Pharmaceuticals Inc (NasdaqGS
GNX) revealed on Wednesday the addition of Dr Karen Ferrante MD, to its board of directors.
Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors
GlobeNewswire - Wed Jan 29, 3:00PM CST
Progenics Pharmaceuticals, Inc. (Nasdaq GNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Karen Ferrante, M.D., a healthcare industry leader with more than two decades of experience in the areas of oncology and clinical research and development, has been elected to its Board of Directors. Most recently Dr. Ferrante held the positions of Chief Medical Officer and was a Head of R & D at Millennium, The Takeda Oncology Company, and Oncology Therapeutic Area Head at Takeda Pharmaceutical Company.
Latest Thyroid Cancer Pipeline Review
M2 - Tue Jan 28, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmc3df/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering. 'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Scope - A snapshot of the global therapeutic scenario for Thyroid Cancer. - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Bio-Path Holdings, Inc. - Eisai Co., Ltd. - Bayer AG - Bionomics Limited - Azaya Therapeutics Incorporated - Vascular Biogenics Ltd. - Biovista Inc. - Trophogen, Inc. - centrose llc - Ecrins Therapeutics SAS For more information visit http://www.researchandmarkets.com/research/zm...oid_cancer
Plague - Latest Pipeline Review Report
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/9r77ph/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H2 2013" report to their offering. 'Plague - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Plague, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plague. Scope - A snapshot of the global therapeutic scenario for Plague. - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Plague pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Plague - Companies Involved in Therapeutics Development - Takeda Pharmaceutical Company Limited - Summit Corporation plc - Mucosis B.V. - iBio, Inc. - Cellceutix Corporation Drug Profiles - rF1V Vaccine - Flagellin/F1/V Vaccine - PMX-30016 - SMT-15000 - Subunit Vaccine For Plague - Plague Vaccine - Yersinia Pestis Vaccine - Subunit Vaccine For Anthrax-Plague Combination - Yersinia Pestis Vaccine - Yersinia Pestis Vaccine - tPA-V DNA Vaccine - Small Molecule to Inhibit YoPH for Plague For more information visit http://www.researchandmarkets.com/research/9r...e_pipeline
Japanese Approval for SGEN/Takeda's Adcetris - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 3:45PM CST
Seattle Genetics and partner Takeda obtained Japanese approval for Adcetris for the treatment of patients with CD30-positive relapsed or refractory HL and ALCL
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
The Zacks Analyst Blog Highlights:Actavis, Sanofi, Takeda Pharmaceutical, Forest Laboratories and Iconix Brand Group
PR Newswire - Tue Mar 04, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Actavis, Inc. (NYSE:ACT-Free Report), Sanofi (NYSE:SNY-Free Report), Takeda Pharmaceutical Company Limited (OTC:TKPYY-Free Report), Forest Laboratories Inc. (NYSE:FRX-Free Report) and Iconix Brand Group Inc. (Nasdaq:ICON-Free Report).
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Actavis Challenges Patents - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 3:45PM CST
Actavis announced that it is seeking FDA approval for its generic versions of Multaq and Colcrys.
Sucampo Gains On Better-Than-Expected Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:20PM CST
Shares of Sucampo Pharmaceuticals gained 11.9% following the release of fourth quarter results on Feb 26, 2014.
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
Takeda Joins The Global CEO Initiative on Alzheimer's Disease
PR Newswire - Thu Feb 20, 9:30AM CST
The Global CEO Initiative (CEOi) on Alzheimer's Disease today announced that Takeda Pharmaceutical Company Limited ("Takeda") will join the CEOi as part of its effort to spur innovations in research and accelerate a means of prevention for Alzheimer's and Dementia, building momentum behind the G8's commitment to stop the disease by 2025.
Alnylam Widens Q4 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 11:00AM CST
Alnylam's fourth quarter 2013 loss of 51 cents per share was wider than the Zacks Consensus Estimate of a loss of 48 cents.
Wider-than-Expected Q4 Loss at AMAG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 9:40AM CST
AMAG's fourth quarter 2013 loss of 17 cents per share was wider than the Zacks Consensus Estimate of a loss of 10 cents.
Seattle Genetics Achieves Sales Milestone Under ADCETRIS(R) (Brentuximab Vedotin) Collaboration with Takeda
Business Wire - Wed Feb 05, 8:00AM CST
Seattle Genetics, Inc. (Nasdaq: SGEN), today announced that it will receive a $5 million milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda). The milestone was triggered by Takeda surpassing annual ADCETRIS net sales of $100 million in its territories. The milestone will be recognized as royalty revenue in the first quarter of 2014.
Concise Analysis of the International Biomarkers - Discovery Techniques and Applications
M2 - Fri Jan 31, 6:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/5nwd88/biomarkers) has announced the addition of the "Concise Analysis of the International Biomarkers - Discovery Techniques and Applications" report to their offering. Biomarker discovery techniques analyzed in this report include Bioimaging, Bioinformatics and Omics Technologies. On a broader geographic level, these technologies further drilled down to Bioimaging - Computed Tomography (CT), Magnetic Resonence Imaging (MRI), Ultrasound and Other; and Omics Technologies - Genomics, Metabolomics, Proteomics and Other. The study also explores the global market for therapeutic areas of biomarkers comprising Cardiology, Neurology, Oncology and Other. The report reviews, analyses and projects the Biomarkers market for global and the regional markets including the United States, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 10 independent countries across Europe - France, Germany, Italy, Spain, Sweden, the United Kingdom; and Asia-Pacific - Australia, China, India and Japan. Accounting for a lion's share of an estimated 47% in 2013, equating to US$18.9 billion, the United States leads the global market for Biomarkers. Growing at a robust compounded annual growth rate of 18.8% during the period 2013-2020, the global market is projected to touch US$63.2 billion. This 350 pages, global market report includes 100 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the market value in US$ by geographic region, biomarker discovery techniques and therapeutic area. Key Topics Covered: Part A: Global Market Perspective 1. Introduction 2. Key Market Trends 3. Key Major Players 4. Key Business Trends 5. Global Market Overview Part B: Regional Market Perspective Regional Market Overview 1. The United States 2. Europe 3. Asia-Pacific 4. Rest Of World Part C: Guide To The Industry 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part D: Annexure 1. Research Methodology 2. Feedback Companies Mentioned: - Abbott Laboratories - Bruker - Celera - Dr. Reddy's Laboratories - EMD Millipore - F. Hoffmann-La Roche - GE Healthcare - Johnson & Johnson - Nordion - Philips Healthcare - Ranbaxy Laboratories - Roche Diagnostics Corporation - Rosetta Genomics - Sanofi - Shimadzu Scientific Instruments - Siemens Healthcare - Siemens Healthcare Diagnostics - Sigma-Aldrich Corporation - Takeda Pharmaceutical Company - Thermo Fisher Scientific - UCB For more information visit http://www.researchandmarkets.com/research/5nwd88/biomarkers
Concise Analysis of the International Biopharmaceuticals Market
M2 - Fri Jan 31, 6:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/rcw555/biopharmaceuticals) has announced the addition of the "Biopharmaceuticals - A Global Market Overview" report to their offering. The pharmaceutical R&D pipeline and industry have been witnessing greater degree of dependence on biopharmaceuticals. Development of these products is being undertaken by a growing number of players in the pharmaceutical industry, which include the big pharma companies as also generic drug manufacturers, who are also engaged in developing biosimilars. In conjunction with the traditional small biopharmaceutical companies, the new bigger entrants have been focused on continually expanding the global biologics pipeline, implying that the number and proportion of new pharmaceuticals being commercialized would increasingly comprise biopharmaceuticals and not small molecule drugs. As the cost of developing biopharmaceuticals and bringing them to market is generally much higher, offering enhanced profit margins, it comes as no surprise that the global pharmaceutical industry would continue to rely on biopharmaceuticals for profits and innovation, in addition to its very survival. Even though the worldwide economic recession has been slow in recovering, the global pharmaceutical and biopharmaceutical industries have marched ahead, showing profitability and growth. According to estimates, more than 10k therapeutics are currently in the research and development stage, which include chemical substance pharmaceuticals or drugs and biotechnology-derived pharmaceuticals or biopharmaceuticals undergoing over 40k clinical trials. Key Topics Covered: Part A: Global Market Perspective 1. Introduction 2. Key Facts And Figures Of Biopharma Industry And Latest Approvals 3. Key Market Trends 4. Key Global Players 5. Key Business Trends 6. Global Market Overview Part B: Regional Market Perspective Regional Market Overview 1. North America 2. Europe 3. Asia-Pacific 4. South America 5. Rest Of World Part C: Guide To The Industry 1. North America 2. Europe 3. Asia-Pacific 4. Rest Of World Part D: Annexure 1. Research Methodology 2. The Questionnaire 3. Feedback Companies Mentioned: - Abbott Laboratories - Amgen - Astrazeneca - BASF - Bayer - Biocon - Biogen - Boehringer Ingelheim - Bristol-Myers Squibb Company - Daiichi Sankyo Company - Eli Lilly and Company - Genentech - Glaxosmithkline - Hospira - Johnson & Johnson - LG Life Sciences - Novartis - Novo Nordisk - Pfizer - Ranbaxy Laboratories - Roche Holding - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - UCB For more information visit http://www.researchandmarkets.com/research/rc...aceuticals
Skin Infections - Pipeline Review, H2 2013 Research Report
M2 - Fri Jan 31, 2:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/dq4mw3/skin_infections) has announced the addition of the "Skin Infections - Pipeline Review, H2 2013" report to their offering. 'Skin Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Infections. Skin Infections - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources Scope - A snapshot of the global therapeutic scenario for Skin Infections. - A review of the Skin Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Skin Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Takeda Pharmaceutical Company Limited Amorepacific Corporation Toyama Chemical Co., Ltd. Foamix Ltd. Anacor Pharmaceuticals, Inc. Lytix Biopharma AS MGB Biopharma Limited Pergamum AB Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/dq...infections About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
10-Q: STARRETT L S CO
Edgar Online - Thu Jan 30, 1:40PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 12-15
Concise Analysis of the International Peptide Therapeutics Market - Forecasts to 2018
M2 - Thu Jan 30, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/v65dnx/peptide) has announced the addition of the "Concise Analysis of the International Peptide Therapeutics Market - Forecasts to 2018" report to their offering. To exploit the emerging international peptide therapeutics market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for peptide molecules since chemotherapy, which is the major mode of treatment for cancer, is facing major challenges due to its inability to deliver the correct amount of drug directly. In addition, it affects the normal cells in the body. Peptide application in various other treatments has opened a promising avenue for future growth of this market. New routes of peptide administration are being investigated; however the parenteral route continues to dominate this market and accounted for a share of almost 86% of the entire market. Similarly, the technology market is ruled by LPPS (long phase peptide syntheses) and is anticipated to decline owing to huge demand for solid phase peptide syntheses and hybrid syntheses. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Global Peptide Therapeutics Market Dynamics 4 Global Peptide Therapeutics Market Analysis, By Applications 5 Global Peptide Therapeutics Market, by Route of Administration 6 Peptide Therapeutics Market - Generic & Innovative Segments 7 API Peptide Therapeutics Market, In-house Vs CMO 8 Peptide Therapeutics Market, By Technology 9 Peptide Therapeutics Market, By Geography 10 Market Share Analysis 11 Recommendations 12 Company Profiles Companies Mentioned: - Amgen - Amylin Pharmaceuticals - Bristol-Myers Squibb - AstraZeneca - Bachem Holding - Eli Lilly and Company - GlaxoSmithKline - Ipsen - Lonza - Merck & Co. - Novartis - Novo-Nordisk - Peptisyntha - Pfizer - PolyPeptide - Roche - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/v65dnx/peptide
Progenics Pharmaceuticals Inc names Dr Karen Ferrante to board
M2 - Thu Jan 30, 3:01AM CST
Oncology company Progenics Pharmaceuticals Inc (NasdaqGS
GNX) revealed on Wednesday the addition of Dr Karen Ferrante MD, to its board of directors. Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors
GlobeNewswire - Wed Jan 29, 3:00PM CST
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Karen Ferrante, M.D., a healthcare industry leader with more than two decades of experience in the areas of oncology and clinical research and development, has been elected to its Board of Directors. Most recently Dr. Ferrante held the positions of Chief Medical Officer and was a Head of R & D at Millennium, The Takeda Oncology Company, and Oncology Therapeutic Area Head at Takeda Pharmaceutical Company. Latest Thyroid Cancer Pipeline Review
M2 - Tue Jan 28, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmc3df/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering. 'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Scope - A snapshot of the global therapeutic scenario for Thyroid Cancer. - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Bio-Path Holdings, Inc. - Eisai Co., Ltd. - Bayer AG - Bionomics Limited - Azaya Therapeutics Incorporated - Vascular Biogenics Ltd. - Biovista Inc. - Trophogen, Inc. - centrose llc - Ecrins Therapeutics SAS For more information visit http://www.researchandmarkets.com/research/zm...oid_cancer
Plague - Latest Pipeline Review Report
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/9r77ph/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H2 2013" report to their offering. 'Plague - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Plague, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plague. Scope - A snapshot of the global therapeutic scenario for Plague. - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Plague pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Plague - Companies Involved in Therapeutics Development - Takeda Pharmaceutical Company Limited - Summit Corporation plc - Mucosis B.V. - iBio, Inc. - Cellceutix Corporation Drug Profiles - rF1V Vaccine - Flagellin/F1/V Vaccine - PMX-30016 - SMT-15000 - Subunit Vaccine For Plague - Plague Vaccine - Yersinia Pestis Vaccine - Subunit Vaccine For Anthrax-Plague Combination - Yersinia Pestis Vaccine - Yersinia Pestis Vaccine - tPA-V DNA Vaccine - Small Molecule to Inhibit YoPH for Plague For more information visit http://www.researchandmarkets.com/research/9r...e_pipeline
Japanese Approval for SGEN/Takeda's Adcetris - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 3:45PM CST
Seattle Genetics and partner Takeda obtained Japanese approval for Adcetris for the treatment of patients with CD30-positive relapsed or refractory HL and ALCL
(0)
(0)Takeda Pharmaceutical Co., Ltd. (TAK) Stock Research Links
Scroll down for more posts ▼